Meeting: Advisory Board on Radiation and Worker Health (ABRWH), Subcommittee for Dose Reconstruction Reviews (SDRR), National Institute for Occupational Safety and Health (NIOSH), 43548-43549 [2021-16954]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
43548
Federal Register / Vol. 86, No. 150 / Monday, August 9, 2021 / Notices
Broadcom from retaliating against a
customer that refuses a prohibited
majority share requirement or that
purchases products from a competitor of
Broadcom.
Paragraph I of the proposed order
defines the key terms used in the order.
Paragraph II.A. of the proposed order
prohibits Broadcom from imposing a
majority share requirement on a
customer’s purchases of any
Monopolized Product. This provision is
designed to end Broadcom’s exclusive
dealing practices in the markets for
Monopolized Products and to enable the
emergence of effective competition in
those markets. The prohibition applies
to sales of Monopolized Products to
OEMs and to U.S. service providers. The
proposed order specifically includes
prohibitions on Broadcom (1)
conditioning the sale of a Monopolized
Product on a majority share requirement
for that product, (2) conditioning price
terms, or non-price terms such as
delivery or support terms, for a
Monopolized Product on a majority
share requirement for that product, (3)
conditioning other payments on a
majority share requirement for a
Monopolized Product, or (4) providing
certain types of retroactive rebates for a
Monopolized Product in exchange for a
majority share requirement.
The prohibitions in Paragraph II.A.
are qualified by a number of provisos
designed to assure that the order does
not bar Broadcom from competing on
the merits. The first proviso clarifies
that the order does not prohibit
Broadcom from fulfilling orders from a
customer that, over time, chooses to
purchase more than 50% of its
requirements from Broadcom, provided
that such purchases are not pursuant to
a majority share requirement prohibited
by the order. The second proviso
clarifies that a customer’s mere
designation of Broadcom as an
‘‘authorized’’ or ‘‘preferred’’ provider
does not alone establish a violation of
the order. The third proviso clarifies
that the order does not prohibit nonretroactive volume discounts. The
fourth proviso allows Broadcom, in
narrow circumstances, to enter into a
majority share requirement in
connection with a particular request for
proposal (RFP). The proviso provides
that Broadcom may agree to a singlesource term in connection with an RFP
covering a single device model (or a
single device model and certain limited
derivatives thereof) if the customer
structures the RFP in this way. (In
contrast, if a customer chooses to
structure an RFP to split component
supply for a particular device among
multiple suppliers, Broadcom may not
VerDate Sep<11>2014
17:26 Aug 06, 2021
Jkt 253001
thwart this by insisting on exclusivity.)
The fifth proviso enables Broadcom, in
specified conditions, to agree to
exclusivity terms with a customer to
incent Broadcom to continue producing
a product beyond its ordinary-course
end of life.
Paragraph II.B of the proposed order
prohibits Broadcom from using its
monopoly power in a Monopolized
Product to impose majority share
requirements for other Monopolized
Products or Related Products.
Paragraph II.C of the order prohibits
Broadcom from retaliating against a
customer for working with a Broadcom
rival or for refusing to commit to or
maintain a prohibited majority share
requirement. Prohibited retaliation
includes actual or threatened
interference with the sale or delivery of
Monopolized Products; withdrawal or
modification of, or refusal to extend,
relatively favorable price or non-price
terms; or refusal to deal with the
customer on terms generally available to
other similarly situated customers.
The proposed order contains standard
provisions designed to ensure
compliance. Paragraph III requires
Broadcom to maintain an antitrust
compliance program and to provide
notice to customers of the prohibitions
contained in the order. Paragraphs IV
through VI contain provisions regarding
compliance reports, notice of changes in
respondent, and access to documents
and personnel.
The proposed Order’s prohibitions
apply to agreements with Service
Providers that serve end users in the
United States and to agreements with
OEMs worldwide, with the exception of
agreements for the sale of products
intended for use in devices for end users
in China. These products are excluded
from the prohibitions on majority share
requirements in light of distinct
competitive conditions applicable to
them. The term of the proposed order is
ten years.
By direction of the Commission.
Joel Christie,
Acting Secretary.
[FR Doc. 2021–16655 Filed 8–6–21; 8:45 am]
BILLING CODE 6750–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Meeting: Advisory Board on Radiation
and Worker Health (ABRWH),
Subcommittee for Dose
Reconstruction Reviews (SDRR),
National Institute for Occupational
Safety and Health (NIOSH)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Subcommittee for Dose
Reconstruction Reviews (SDRR) of the
Advisory Board on Radiation and
Worker Health (ABRWH or the Advisory
Board). This meeting is open to the
public, but without a public comment
period. The public is welcome to submit
written comments in advance of the
meeting, to the contact person below.
Written comments received in advance
of the meeting will be included in the
official record of the meeting. The
public is also welcomed to listen to the
meeting by joining the audio conference
(information below). The audio
conference line has 150 ports for callers.
DATES: The meeting will be held on
September 29, 2021, from 10:30 a.m. to
4:00 p.m., EDT. Written comments must
be received on or before September 22,
2021.
ADDRESSES: You may submit comments
by mail to: Sherri Diana, National
Institute for Occupational Safety and
Health, 1090 Tusculum Avenue, MS
C–34, Cincinnati, Ohio 45226.
Meeting Information: Audio
Conference Call via FTS Conferencing.
The USA toll-free dial-in number is
1–866–659–0537; the pass code is
9933701.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Rashaun Roberts, Ph.D., Designated
Federal Officer, NIOSH, CDC, 1090
Tusculum Avenue, Mailstop C–24,
Cincinnati, Ohio 45226, Telephone:
(513) 533–6800; Toll Free 1(800)CDC–
INFO; Email: ocas@cdc.gov.
SUPPLEMENTARY INFORMATION:
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
E:\FR\FM\09AUN1.SGM
09AUN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 150 / Monday, August 9, 2021 / Notices
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that
have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC). In
December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS,
which subsequently delegated this
authority to CDC. NIOSH implements
this responsibility for CDC.
The Advisory Board’s charter was
issued on August 3, 2001, renewed at
appropriate intervals, and rechartered
under Executive Order 13889 on March
22, 2020, and will terminate on March
22, 2022.
Purpose: The Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
SDRR was established to aid the
Advisory Board in carrying out its duty
to advise the Secretary, HHS, on dose
reconstruction.
Matters To Be Considered: The agenda
will include discussions on the
following dose reconstruction program
quality management and assurance
activities: Dose reconstruction cases
under review from Set 29, possibly
including cases involving: Albuquerque
Operations Office, Area IV of the Santa
Susana Field Laboratory, Argonne
National Laboratory-East, Argonne
National Laboratory-West, Battelle
Laboratories-King Avenue, Clarksville
Modification Center, Feed Materials
Production Center (FMPC), Fermi
National Accelerator Laboratory,
General Atomics, Hanford, Idaho
National Laboratory, Lawrence Berkeley
National Laboratory, Lawrence
Livermore National Laboratory, Los
Alamos National Laboratory, Mound
VerDate Sep<11>2014
17:26 Aug 06, 2021
Jkt 253001
Plant, Nevada Test Site, Oak Ridge
Gaseous Diffusion Plant (K–25), Oak
Ridge Institute for Science and
Education, Oak Ridge National
Laboratory (X–10), Pacific Northwest
National Laboratory, Paducah Gaseous
Diffusion Plant, Pantex Plant,
Portsmouth Gaseous Diffusion Plant,
Rocky Flats Plant, Savannah River Site,
and/or Y–12 Plant. If time permits, there
may also be discussion on professional
judgement in response to the April 12,
2021 SDRR report to the Advisory
Board. Agenda items are subject to
change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–16954 Filed 8–6–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Community Living
Agency Information Collection
Activities; Proposed Collection; Public
Comment Request; Centers for
Independent Living Program
Performance Report (0985–0061)
Administration for Community
Living, Health and Human Services
(HHS).
AGENCY:
ACTION:
Notice.
The Administration for
Community Living (ACL) is announcing
an opportunity for the public to
comment on the proposed collection of
information listed above. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish a notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This Proposed Extension
without Revision of a Currently
Approved Collection (ICR Ext) solicits
comments on the information collection
requirements relating to the Centers for
SUMMARY:
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
43549
Independent Living under the
Rehabilitation Act of 1973.
DATES: Comments on the collection of
information must be submitted
electronically by 11:59 p.m. (EST) or
postmarked by October 8, 2021.
ADDRESSES: Submit electronic
comments on the collection of
information to: Peter Nye at
OILPPRAComments@acl.hhs.gov.
Submit written comments on the
collection of information to
Administration for Community Living,
Washington, DC 20201, Attention: Peter
Nye.
FOR FURTHER INFORMATION CONTACT:
Peter Nye, Administration for
Community Living, Washington, DC
20024, (202) 795–7606 or
OILPPRAComments@acl.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, ACL is publishing a notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, ACL invites
comments on our burden estimates or
any other aspect of this collection of
information, including:
(1) Whether the proposed collection
of information is necessary for the
proper performance of ACL’s functions,
including whether the information will
have practical utility;
(2) the accuracy of ACL’s estimate of
the burden of the proposed collection of
information, including the validity of
the methodology and assumptions used
to determine burden estimates; (3) ways
to enhance the quality, utility, and
clarity of the information to be
collected; and
(4) ways to minimize the burden of
the collection of information on
respondents, including through the use
of automated collection techniques
when appropriate, and other forms of
information technology.
E:\FR\FM\09AUN1.SGM
09AUN1
]]>Agencies
[Federal Register Volume 86, Number 150 (Monday, August 9, 2021)]
[Notices]
[Pages 43548-43549]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16954]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Meeting: Advisory Board on Radiation and Worker Health (ABRWH),
Subcommittee for Dose Reconstruction Reviews (SDRR), National Institute
for Occupational Safety and Health (NIOSH)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Subcommittee for Dose
Reconstruction Reviews (SDRR) of the Advisory Board on Radiation and
Worker Health (ABRWH or the Advisory Board). This meeting is open to
the public, but without a public comment period. The public is welcome
to submit written comments in advance of the meeting, to the contact
person below. Written comments received in advance of the meeting will
be included in the official record of the meeting. The public is also
welcomed to listen to the meeting by joining the audio conference
(information below). The audio conference line has 150 ports for
callers.
DATES: The meeting will be held on September 29, 2021, from 10:30 a.m.
to 4:00 p.m., EDT. Written comments must be received on or before
September 22, 2021.
ADDRESSES: You may submit comments by mail to: Sherri Diana, National
Institute for Occupational Safety and Health, 1090 Tusculum Avenue, MS
C-34, Cincinnati, Ohio 45226.
Meeting Information: Audio Conference Call via FTS Conferencing.
The USA toll-free dial-in number is 1-866-659-0537; the pass code is
9933701.
FOR FURTHER INFORMATION CONTACT: Rashaun Roberts, Ph.D., Designated
Federal Officer, NIOSH, CDC, 1090 Tusculum Avenue, Mailstop C-24,
Cincinnati, Ohio 45226, Telephone: (513) 533-6800; Toll Free 1(800)CDC-
INFO; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Background: The Advisory Board was established under the Energy
Employees Occupational Illness Compensation Program Act of 2000 to
advise the President on a variety of policy and technical functions
required to implement and effectively manage the new compensation
program. Key
[[Page 43549]]
functions of the Advisory Board include providing advice on the
development of probability of causation guidelines that have been
promulgated by the Department of Health and Human Services (HHS) as a
final rule; advice on methods of dose reconstruction, which have also
been promulgated by HHS as a final rule; advice on the scientific
validity and quality of dose estimation and reconstruction efforts
being performed for purposes of the compensation program; and advice on
petitions to add classes of workers to the Special Exposure Cohort
(SEC). In December 2000, the President delegated responsibility for
funding, staffing, and operating the Advisory Board to HHS, which
subsequently delegated this authority to CDC. NIOSH implements this
responsibility for CDC.
The Advisory Board's charter was issued on August 3, 2001, renewed
at appropriate intervals, and rechartered under Executive Order 13889
on March 22, 2020, and will terminate on March 22, 2022.
Purpose: The Advisory Board is charged with (a) providing advice to
the Secretary, HHS, on the development of guidelines under Executive
Order 13179; (b) providing advice to the Secretary, HHS, on the
scientific validity and quality of dose reconstruction efforts
performed for this program; and (c) upon request by the Secretary, HHS,
advise the Secretary on whether there is a class of employees at any
Department of Energy facility who were exposed to radiation but for
whom it is not feasible to estimate their radiation dose, and on
whether there is reasonable likelihood that such radiation doses may
have endangered the health of members of this class. SDRR was
established to aid the Advisory Board in carrying out its duty to
advise the Secretary, HHS, on dose reconstruction.
Matters To Be Considered: The agenda will include discussions on
the following dose reconstruction program quality management and
assurance activities: Dose reconstruction cases under review from Set
29, possibly including cases involving: Albuquerque Operations Office,
Area IV of the Santa Susana Field Laboratory, Argonne National
Laboratory-East, Argonne National Laboratory-West, Battelle
Laboratories-King Avenue, Clarksville Modification Center, Feed
Materials Production Center (FMPC), Fermi National Accelerator
Laboratory, General Atomics, Hanford, Idaho National Laboratory,
Lawrence Berkeley National Laboratory, Lawrence Livermore National
Laboratory, Los Alamos National Laboratory, Mound Plant, Nevada Test
Site, Oak Ridge Gaseous Diffusion Plant (K-25), Oak Ridge Institute for
Science and Education, Oak Ridge National Laboratory (X-10), Pacific
Northwest National Laboratory, Paducah Gaseous Diffusion Plant, Pantex
Plant, Portsmouth Gaseous Diffusion Plant, Rocky Flats Plant, Savannah
River Site, and/or Y-12 Plant. If time permits, there may also be
discussion on professional judgement in response to the April 12, 2021
SDRR report to the Advisory Board. Agenda items are subject to change
as priorities dictate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-16954 Filed 8-6-21; 8:45 am]
BILLING CODE 4163-18-P
